|
humans |
54 |
|
female |
47 |
|
middle aged |
34 |
|
ovarian cancer |
34 |
|
adult |
33 |
|
aged |
27 |
|
pregnancy |
24 |
|
cervical cancer |
23 |
|
immunohistochemistry |
23 |
|
chemotherapy |
22 |
|
gestational trophoblastic disease |
22 |
|
gestational trophoblastic neoplasia |
20 |
|
prognosis |
20 |
|
hong kong - epidemiology |
19 |
|
human papillomavirus |
19 |
|
molecular sequence data |
19 |
|
genetic predisposition to disease |
18 |
|
adolescent |
17 |
|
animals |
17 |
|
cohort studies |
17 |
|
reverse transcriptase polymerase chain reaction |
17 |
|
aged, 80 and over |
16 |
|
choriocarcinoma |
16 |
|
neoplasm staging |
16 |
|
apoptosis |
15 |
|
cell proliferation |
15 |
|
gene expression regulation, neoplastic |
15 |
|
polymerase chain reaction |
15 |
|
risk factors |
15 |
|
cell line, tumor |
14 |
|
chinese |
14 |
|
hydatidiform mole |
14 |
|
antigens, cd - genetics |
13 |
|
base sequence |
13 |
|
cell adhesion molecules - genetics |
13 |
|
dna methylation |
13 |
|
l-lactate dehydrogenase - blood |
13 |
|
polymorphism, single nucleotide - genetics |
13 |
|
sensitivity and specificity |
13 |
|
breast cancer |
12 |
|
endometrial cancer |
12 |
|
hysterectomy |
12 |
|
tumor cells, cultured |
12 |
|
tumor markers, biological - analysis |
12 |
|
blotting, western |
11 |
|
brca1 protein - genetics |
11 |
|
case-control studies |
11 |
|
cell adhesion molecules - genetics - metabolism |
11 |
|
cercopithecus aethiops |
11 |
|
china |
11 |
|
cho cells - virology |
11 |
|
colposcopy |
11 |
|
coronavirus |
11 |
|
cricetinae |
11 |
|
cricetulus |
11 |
|
disease progression |
11 |
|
endometrial carcinoma |
11 |
|
homozygote |
11 |
|
intestine, small - physiology |
11 |
|
lectins, c-type - genetics - metabolism |
11 |
|
lung - physiology - virology |
11 |
|
medical sciences |
11 |
|
mutation - genetics |
11 |
|
promoter regions, genetic |
11 |
|
proteasome endopeptidase complex - metabolism |
11 |
|
receptors, cell surface - genetics - metabolism |
11 |
|
rna, messenger - metabolism |
11 |
|
sars coronavirus |
11 |
|
sars virus - metabolism - pathogenicity |
11 |
|
severe acute respiratory syndrome - epidemiology - genetics |
11 |
|
species index: animalia |
11 |
|
tandem repeat sequences |
11 |
|
vero cells - virology |
11 |
|
cervical screening |
10 |
|
dna, neoplasm - genetics |
10 |
|
gestational age |
10 |
|
hong kong |
10 |
|
leiomyosarcoma |
10 |
|
male |
10 |
|
ovarian neoplasms - genetics - metabolism - pathology |
10 |
|
prevalence |
10 |
|
transcription, genetic |
10 |
|
cervical intraepithelial neoplasia |
9 |
|
contrast-enhanced ct |
9 |
|
diagnosis, differential |
9 |
|
dna mutational analysis |
9 |
|
dna, viral - genetics |
9 |
|
drug resistance, neoplasm |
9 |
|
genes, tumor suppressor |
9 |
|
genotype |
9 |
|
ovarian neoplasms - genetics |
9 |
|
ovarian neoplasms - genetics - pathology |
9 |
|
phosphorylation |
9 |
|
screening |
9 |
|
survival analysis |
9 |
|
tumor markers, biological - metabolism |
9 |
|
carcinoma - genetics - pathology |
8 |
|
cell line, transformed |
8 |
|
cervical cancer screening |
8 |
|
choriocarcinoma - genetics |
8 |
|
dna hypermethylation |
8 |
|
dna primers |
8 |
|
epithelial ovarian cancer |
8 |
|
estrogen receptor alpha - genetics - metabolism |
8 |
|
genes, p53 - genetics |
8 |
|
gli1 |
8 |
|
hpv |
8 |
|
hydatidiform mole - genetics |
8 |
|
hydatidiform mole - genetics - pathology |
8 |
|
in situ nick-end labeling |
8 |
|
nuclear proteins - genetics - metabolism |
8 |
|
ovarian carcinoma |
8 |
|
p53 |
8 |
|
prognostic marker |
8 |
|
promoter regions, genetic - genetics |
8 |
|
retrospective studies |
8 |
|
signal transduction |
8 |
|
telomerase |
8 |
|
uterine neoplasms - genetics - pathology |
8 |
|
analgesia |
7 |
|
antigens, neoplasm |
7 |
|
asian continental ancestry group - genetics |
7 |
|
baby-friendly hospital initiative |
7 |
|
baby-friendly initiative |
7 |
|
biopsy, needle |
7 |
|
breast neoplasms - epidemiology - genetics |
7 |
|
breastfeeding |
7 |
|
cell cycle proteins - analysis |
7 |
|
cell line |
7 |
|
cervix uteri - virology |
7 |
|
chromosome aberrations |
7 |
|
cisplatin - pharmacology |
7 |
|
community |
7 |
|
diagnostic biomarker |
7 |
|
diffusion magnetic resonance imaging |
7 |
|
dna, mitochondrial - genetics |
7 |
|
dna-binding proteins |
7 |
|
ehealth |
7 |
|
epithelioid |
7 |
|
follow-up studies |
7 |
|
gene amplification |
7 |
|
gene expression profiling |
7 |
|
gene expression regulation, neoplastic - genetics |
7 |
|
genes, brca1 |
7 |
|
genes, brca2 |
7 |
|
genital neoplasms, female - metabolism - pathology |
7 |
|
gestational |
7 |
|
gestational trophoblastic disease - metabolism - pathology |
7 |
|
health economic analysis |
7 |
|
health literacy |
7 |
|
hedgehog |
7 |
|
hydatidiform mole - metabolism - pathology |
7 |
|
immunoenzyme techniques |
7 |
|
in situ hybridization |
7 |
|
karyotyping |
7 |
|
ki-67 antigen - analysis |
7 |
|
ki67 |
7 |
|
methylation |
7 |
|
microrna |
7 |
|
molar pregnancy |
7 |
|
morphine consumption |
7 |
|
mutation |
7 |
|
neoadjuvant chemotherapy |
7 |
|
neoplasm metastasis |
7 |
|
oncology |
7 |
|
ovarian neoplasms - metabolism - pathology |
7 |
|
ovary - pathology |
7 |
|
placebo |
7 |
|
placenta - metabolism |
7 |
|
polymorphism, genetic - genetics |
7 |
|
proliferation |
7 |
|
rct |
7 |
|
repressor proteins - biosynthesis |
7 |
|
self-sampling |
7 |
|
serms |
7 |
|
sex education |
7 |
|
sexual health |
7 |
|
somatic mutations |
7 |
|
stakeholders |
7 |
|
transcription factors - genetics - metabolism |
7 |
|
trophoblastic |
7 |
|
tumors |
7 |
|
uterine cervical neoplasms |
7 |
|
women's health |
7 |
|
adenocarcinoma - genetics - metabolism - pathology |
6 |
|
anti-müllerian hormone |
6 |
|
apoptosis - drug effects - physiology |
6 |
|
asian continental ancestry group |
6 |
|
azacitidine - analogs & derivatives - pharmacology |
6 |
|
biopsy |
6 |
|
brca1 |
6 |
|
c-mos |
6 |
|
carcinogenesis |
6 |
|
carcinoma, squamous cell - genetics |
6 |
|
carcinoma, squamous cell - genetics - virology |
6 |
|
caspases - metabolism |
6 |
|
cell adhesion - physiology |
6 |
|
cell migration |
6 |
|
cell nucleus - metabolism |
6 |
|
cell proliferation - drug effects |
6 |
|
checkpoint inhibitor |
6 |
|
china - ethnology |
6 |
|
chromosome in situ hybridization |
6 |
|
cin |
6 |
|
combined modality therapy |
6 |
|
comparative genomic hybridization |
6 |
|
co‐testing |
6 |
|
cpg islands |
6 |
|
cyclin-dependent kinase inhibitor p21 |
6 |
|
differential gene expression |
6 |
|
dual specificity phosphatase 6 - antagonists & inhibitors - genetics - metabolism |
6 |
|
endometrial neoplasms - genetics - metabolism |
6 |
|
epigenesis, genetic |
6 |
|
estrogen receptors |
6 |
|
exons |
6 |
|
gene expression |
6 |
|
genes, p53 |
6 |
|
genital neoplasms, female - genetics |
6 |
|
germ cell tumor |
6 |
|
gynaecological cancer |
6 |
|
gynecological neoplasm |
6 |
|
hedgehog proteins - genetics - metabolism |
6 |
|
helix-loop-helix motifs |
6 |
|
high-grade tumor |
6 |
|
hpv testing |
6 |
|
hydrogen peroxide - metabolism |
6 |
|
id proteins |
6 |
|
immunotherapy |
6 |
|
inhibitor of differentiation protein 1 |
6 |
|
lymphadenectomy |
6 |
|
malignant ovarian germ cell tumors |
6 |
|
management |
6 |
|
metallothionein - genetics - metabolism |
6 |
|
metallothionein 1e gene |
6 |
|
metastasis |
6 |
|
mice |
6 |
|
microdissection |
6 |
|
microsatellite repeats - genetics |
6 |
|
mir-141 |
6 |
|
mitogen-activated protein kinase 1 - antagonists & inhibitors - metabolism |
6 |
|
mitogen-activated protein kinase 3 - antagonists & inhibitors - metabolism |
6 |
|
neoplasm proteins - genetics - metabolism |
6 |
|
neoplasm recurrence, local |
6 |
|
neoplasms |
6 |
|
nf-κb signaling |
6 |
|
observer variation |
6 |
|
oligonucleotide array sequence analysis |
6 |
|
ovarian neoplasms |
6 |
|
ovarian neoplasms - drug therapy - genetics - pathology |
6 |
|
ovarian neoplasms - drug therapy - pathology |
6 |
|
ovarian reserve |
6 |
|
oxidative stress - physiology |
6 |
|
p63 |
6 |
|
papillomaviridae - genetics |
6 |
|
papillomavirus infections - diagnosis - virology |
6 |
|
papillomavirus infections - epidemiology - ethnology - virology |
6 |
|
pd-l1 |
6 |
|
placenta - chemistry |
6 |
|
placenta - metabolism - pathology |
6 |
|
ploidies |
6 |
|
promoter hypermethylation |
6 |
|
proto-oncogene proteins c-mos - biosynthesis |
6 |
|
quality of life |
6 |
|
reproducibility of results |
6 |
|
reverse transcriptase polymerase chain reaction - methods |
6 |
|
rna, messenger - antagonists & inhibitors - genetics - metabolism |
6 |
|
rna, neoplasm - analysis |
6 |
|
sequence analysis, dna |
6 |
|
signal transduction - drug effects |
6 |
|
survival |
6 |
|
survival rate |
6 |
|
tak1 |
6 |
|
transcription factors - biosynthesis |
6 |
|
trophoblastic tumor |
6 |
|
trophoblastic tumor, placental site - genetics - metabolism - pathology |
6 |
|
trophoblasts - chemistry - pathology |
6 |
|
tumor suppressor protein p53 - analysis |
6 |
|
tumor suppressor proteins |
6 |
|
tumourigenicity |
6 |
|
ubiquitin - metabolism |
6 |
|
uterine cervical neoplasms - genetics |
6 |
|
uterine cervical neoplasms - genetics - metabolism - pathology |
6 |
|
uterine cervical neoplasms - pathology |
6 |
|
uterine neoplasms - genetics - metabolism - pathology |
6 |
|
uterus |
6 |
|
vaginal smears |
6 |
|
vulvar neoplasms - genetics - virology |
6 |
|
zic2 |
6 |
|
abdominal pregnancy |
5 |
|
acquired chemoresistance |
5 |
|
adenocarcinoma, clear cell - genetics - metabolism - pathology |
5 |
|
animal experiment |
5 |
|
animal model |
5 |
|
anoikis resistance |
5 |
|
antigens, polyomavirus transforming - genetics |
5 |
|
antimetabolites, antineoplastic - pharmacology |
5 |
|
antineoplastic-agents-pharmacology |
5 |
|
aorta |
5 |
|
apoptosis regulatory proteins |
5 |
|
apoptosis regulatory proteins - genetics - metabolism |
5 |
|
ascites |
5 |
|
biological markers - analysis |
5 |
|
blotting, northern |
5 |
|
blotting, western - methods |
5 |
|
blu |
5 |
|
breast cancer risk |
5 |
|
breast neoplasms - diagnosis - prevention & control |
5 |
|
breast neoplasms - genetics |
5 |
|
c-dna array |
5 |
|
calcium-calmodulin-dependent protein kinases - genetics |
5 |
|
cancer metabolism |
5 |
|
cancer prognosis |
5 |
|
cancer stem cell |
5 |
|
cancer survivorship |
5 |
|
carcinoma, endometrioid - enzymology - genetics |
5 |
|
carcinoma, endometrioid - enzymology - genetics - metabolism - pathology |
5 |
|
carcinoma, endometrioid - enzymology - genetics - pathology |
5 |
|
carcinoma, endometrioid - genetics - metabolism - pathology |
5 |
|
carcinoma, squamous cell - ethnology - genetics - virology |
5 |
|
carcinosarcoma |
5 |
|
cd55 |
5 |
|
cd8+ t cell |
5 |
|
cdna microarray |
5 |
|
cell culture techniques - methods |
5 |
|
cell cycle proteins |
5 |
|
cell cycle proteins - analysis - genetics |
5 |
|
cell differentiation |
5 |
|
cell division - drug effects |
5 |
|
cell invasion and proliferation |
5 |
|
cervical epithelial cells |
5 |
|
cervical intra-epithelial neoplasia |
5 |
|
cervical intraepithelial neoplasia - ethnology - genetics - virology |
5 |
|
cervix |
5 |
|
cervix uteri - chemistry - metabolism |
5 |
|
chemoradiotherapy |
5 |
|
chemoresistance |
5 |
|
choriocarcinoma-pathology |
5 |
|
chorionic gonadotropin - blood |
5 |
|
chromosome painting |
5 |
|
confidence intervals |
5 |
|
cyclin-dependent kinase inhibitor p21 - antagonists and inhibitors - genetics |
5 |
|
cystadenocarcinoma, mucinous - genetics - metabolism - pathology |
5 |
|
cystadenocarcinoma, serous - genetics - metabolism - pathology |
5 |
|
cytogenetic analysis - methods |
5 |
|
cytology |
5 |
|
dalys |
5 |
|
dapk |
5 |
|
decorin |
5 |
|
dichloroacetate dca |
5 |
|
dna replication |
5 |
|
dna, complementary - analysis |
5 |
|
dna, neoplasm |
5 |
|
dna, neoplasm - blood |
5 |
|
dna, neoplasm - chemistry - genetics - metabolism |
5 |
|
dna, viral - analysis |
5 |
|
dna-binding proteins - analysis |
5 |
|
dna-binding proteins - genetics - metabolism |
5 |
|
dnmt1 |
5 |
|
e-cadherin |
5 |
|
ectopic pregnancy |
5 |
|
endometrial neoplasms - enzymology - genetics |
5 |
|
endometrial neoplasms - enzymology - genetics - metabolism - pathology |
5 |
|
endometrial neoplasms - enzymology - genetics - pathology |
5 |
|
endometrial neoplasms - metabolism - pathology |
5 |
|
endometrial stromal sarcoma |
5 |
|
endometrium |
5 |
|
epithelial cells - cytology - metabolism |
5 |
|
evaluation studies as topic |
5 |
|
fear of cancer recurrence |
5 |
|
fibrosis |
5 |
|
forkhead transcription factors - analysis - genetics |
5 |
|
forkhead transcription factors - analysis - genetics - physiology |
5 |
|
foxg1 |
5 |
|
foxm1 |
5 |
|
gene expression regulation, enzymologic |
5 |
|
gene expression regulation, neoplastic - radiation effects |
5 |
|
gene frequency |
5 |
|
genes, p16 |
5 |
|
genes, ras |
5 |
|
genes, viral - genetics |
5 |
|
genetic predisposition to disease - genetics |
5 |
|
genitalia, female - cytology |
5 |
|
genotyping |
5 |
|
gestational trophoblastic disease - genetics - metabolism - pathology |
5 |
|
gestational trophoblastic disease - genetics - pathology |
5 |
|
glutathione s-transferase pi |
5 |
|
glutathione transferase - analysis - genetics - metabolism |
5 |
|
glutathione transferase - genetics |
5 |
|
grb7 |
5 |
|
gynecological cancer |
5 |
|
hdab2ip |
5 |
|
health care surveys |
5 |
|
hemoperitoneum |
5 |
|
hereditary breast cancer |
5 |
|
hexokinase ii |
5 |
|
hormonal treatment |
5 |
|
hpv-negative |
5 |
|
hpv‐e6 |
5 |
|
human papillomavirus 16 - genetics |
5 |
|
human papillomavirus 18 - genetics |
5 |
|
hydatidiform mole - diagnosis - genetics - pathology |
5 |
|
hydatidiform mole - genetics - pathology - surgery |
5 |
|
iatrogenesis |
5 |
|
iatrogenic disease - epidemiology |
5 |
|
immortalization |
5 |
|
immunohistochemical staining |
5 |
|
in situ hybridization - methods |
5 |
|
in vitro culture |
5 |
|
inflammation |
5 |
|
interval debulking surgery |
5 |
|
intracellular signaling peptides and proteins |
5 |
|
isoenzymes - genetics |
5 |
|
jag1-notch1 |
5 |
|
keratins - metabolism |
5 |
|
ki-67 antigen - biosynthesis |
5 |
|
klf12 |
5 |
|
leiomyoma with bizarre nuclei |
5 |
|
logistic models |
5 |
|
loss of heterozygosity |
5 |
|
magnetic resonance imaging |
5 |
|
mass screening - utilization |
5 |
|
mcl-1 |
5 |
|
mcm7 |
5 |
|
mdm2 |
5 |
|
metastatic partial mole |
5 |
|
mgmt |
5 |
|
microsatellite repeats |
5 |
|
minichromosome maintenance protein 7 (mcm7) |
5 |
|
mir-199b-5p |
5 |
|
multivariate analysis |
5 |
|
neo-adjuvant chemotherapy |
5 |
|
neoplasm invasiveness |
5 |
|
nerve tissue proteins - analysis - genetics - physiology |
5 |
|
nuclear proteins |
5 |
|
nuclear proteins - analysis |
5 |
|
o(6)-methylguanine-dna methyltransferase - genetics |
5 |
|
obstetrics and gynecology medical sciences |
5 |
|
odds ratio |
5 |
|
oncogenes - genetics |
5 |
|
ovarian neoplasms - pathology |
5 |
|
ovary |
5 |
|
ovary - metabolism - pathology |
5 |
|
oviduct |
5 |
|
oxidoreductases |
5 |
|
p-p53 (ser15) |
5 |
|
p16 |
5 |
|
p16ink4a |
5 |
|
p21waf1/cip1 |
5 |
|
palb2 mutation |
5 |
|
papillomaviridae |
5 |
|
papillomaviridae - classification - isolation & purification |
5 |
|
papillomaviridae - isolation & purification |
5 |
|
papillomavirus infections - ethnology - genetics |
5 |
|
patient-initiated follow-up |
5 |
|
pcna |
5 |
|
pd-1 |
5 |
|
pdk1 |
5 |
|
peritoneal dialysis |
5 |
|
peritonitis |
5 |
|
pet/ct |
5 |
|
phenotype |
5 |
|
phosphohistone-h3 |
5 |
|
placenta - anatomy & histology |
5 |
|
polymorphism, genetic |
5 |
|
polymorphism, restriction fragment length |
5 |
|
polymorphism, single nucleotide |
5 |
|
precancerous conditions - ethnology - genetics - virology |
5 |
|
probability |
5 |
|
proliferating cell nuclear antigen - biosynthesis |
5 |
|
promoter cpg island hypermethylation |
5 |
|
proteins - genetics |
5 |
|
proteins - metabolism |
5 |
|
proto-oncogene proteins c-bcl-2 - genetics - metabolism |
5 |
|
public health and safety |
5 |
|
pyruvate kinase |
5 |
|
random cervical biopsy |
5 |
|
ras gtpase-activating proteins - metabolism |
5 |
|
rassf1a |
5 |
|
rassf2a |
5 |
|
repressor proteins - metabolism |
5 |
|
reproduction |
5 |
|
rna, messenger - genetics - metabolism |
5 |
|
smooth muscle tumour of uncertain malignant potential |
5 |
|
sp1 |
5 |
|
squamous intraepithelial lesion |
5 |
|
standardized uptake value |
5 |
|
statistics, nonparametric |
5 |
|
stemness |
5 |
|
supportive care needs |
5 |
|
survivin |
5 |
|
t cells |
5 |
|
tgf-β |
5 |
|
tissue array analysis |
5 |
|
tissue microarray |
5 |
|
transfection |
5 |
|
transforming growth factor beta - pharmacology |
5 |
|
tretinoin-pharmacology |
5 |
|
trophoblastic neoplasms - metabolism - pathology |
5 |
|
tumor markers, biological - genetics |
5 |
|
tumor suppressor proteins - metabolism |
5 |
|
tumor virus infections - diagnosis |
5 |
|
up-regulation |
5 |
|
uterine cervical neoplasms - blood - enzymology - genetics |
5 |
|
uterine cervical neoplasms - diagnosis - prevention & control |
5 |
|
uterine cervical neoplasms - ethnology - genetics - virology |
5 |
|
uterine neoplasms |
5 |
|
uterine neoplasms - diagnosis - genetics - pathology |
5 |
|
uterine neoplasms - genetics - pathology - surgery |
5 |
|
uterine neoplasms - metabolism - pathology |
5 |
|
uterine sarcoma |
5 |
|
vin |
5 |
|
viral dna integration |
5 |
|
virus integration - genetics |
5 |
|
vulvar cancer |
5 |
|
vulvar dystrophy |
5 |
|
young adult |
5 |
|
2-[18f]fdg pet/ct |
4 |
|
adaptor proteins, signal transducing - genetics |
4 |
|
adenocarcinoma - enzymology |
4 |
|
adenocarcinoma - genetics |
4 |
|
adenocarcinoma - metabolism - pathology |
4 |
|
akt |
4 |
|
alleles |
4 |
|
amp-activated protein kinases |
4 |
|
ampk |
4 |
|
ampk activation |
4 |
|
ampk-β1 |
4 |
|
animal modelanimal tissue |
4 |
|
antibodies - pharmacology |
4 |
|
antineoplastic combined chemotherapy protocols - adverse effects - therapeutic use |
4 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
4 |
|
apoptosis - genetics - physiology |
4 |
|
atr-chk1 |
4 |
|
autophagy |
4 |
|
b-catenin |
4 |
|
bcl-2-associated x protein |
4 |
|
bd onclarity |
4 |
|
beta catenin - metabolism |
4 |
|
blotting, southern |
4 |
|
brca-negative |
4 |
|
brca2 protein |
4 |
|
c-33 a cell line |
4 |
|
c-4-i cell line |
4 |
|
c-erbb2 |
4 |
|
ca 125 |
4 |
|
cadherin-11 |
4 |
|
cadherins - antagonists and inhibitors - genetics - physiology |
4 |
|
cadherins - biosynthesis - metabolism |
4 |
|
cancer aggressiveness |
4 |
|
cancer cell |
4 |
|
cancer stem cells |
4 |
|
cancer-associated fibroblasts |
4 |
|
candidate cancer genes |
4 |
|
carcinoma, hepatocellular - pathology - surgery |
4 |
|
carcinoma, squamous cell - diagnosis - enzymology - virology |
4 |
|
carcinoma, squamous cell - enzymology |
4 |
|
caspases-biosynthesis |
4 |
|
catenins - genetics - metabolism - physiology |
4 |
|
catheter ablation |
4 |
|
cell cycle |
4 |
|
cell invasion |
4 |
|
cell migration and invasion |
4 |
|
cell movement |
4 |
|
centromere |
4 |
|
cervical cancers |
4 |
|
cervical cytology |
4 |
|
cervical intraepithelial neoplasia - diagnosis - enzymology - pathology - virology |
4 |
|
cervical smear |
4 |
|
cervix uteri - metabolism |
4 |
|
chamoc regimen |
4 |
|
chemokines |
4 |
|
chemotherapy response score |
4 |
|
choriocarcinoma - genetics - metabolism |
4 |
|
choriocarcinoma - genetics - pathology |
4 |
|
choriocarcinoma-enzymology |
4 |
|
chorionic gonadotropin, beta subunit, human - metabolism |
4 |
|
chromosomal proteins, non-histone - genetics |
4 |
|
chromosome |
4 |
|
chromosomes, human, pair 11 |
4 |
|
chromosomes, human, pair 12 |
4 |
|
chromosomes, human, pair 17 |
4 |
|
chromosomes, human, pair 5 - genetics |
4 |
|
cisplatin |
4 |
|
cisplatin resistance |
4 |
|
clear cell |
4 |
|
cloning, molecular |
4 |
|
compliance |
4 |
|
concurrent methylation |
4 |
|
cross-sectional studies |
4 |
|
cxcr2 |
4 |
|
cytogenetic study |
4 |
|
cytogenetics |
4 |
|
cytoplasm - enzymology |
4 |
|
death- associated protein kinase |
4 |
|
demethylating agents |
4 |
|
disease-free survival |
4 |
|
dna - chemistry |
4 |
|
dna modification methylases - antagonists & inhibitors |
4 |
|
dna primers - chemistry |
4 |
|
dna primers - genetics |
4 |
|
dna, complementary - metabolism |
4 |
|
dna, neoplasm - metabolism |
4 |
|
dna-directed dna polymerase - genetics |
4 |
|
down-regulation |
4 |
|
duoxa1 |
4 |
|
education |
4 |
|
educational status |
4 |
|
endometrial cancers |
4 |
|
endometrial neoplasms - genetics |
4 |
|
endometrial neoplasms - genetics - metabolism - pathology |
4 |
|
endometrial neoplasms - genetics - pathology - ultrastructure |
4 |
|
endometrial neoplasms - pathology - physiopathology |
4 |
|
enzyme inhibitors - pharmacology |
4 |
|
epigenesis, genetic - physiology |
4 |
|
epigenetic |
4 |
|
epithelial cells - pathology |
4 |
|
erk |
4 |
|
estradiol - pharmacology |
4 |
|
estrogen receptor beta - genetics - metabolism |
4 |
|
extravillous trophoblast |
4 |
|
eye proteins - antagonists & inhibitors - genetics - pharmacology |
4 |
|
fak/erk signaling |
4 |
|
fallopian tube |
4 |
|
fallopian tube neoplasms - pathology |
4 |
|
filter‐in‐situ hybridization |
4 |
|
first-trimester |
4 |
|
follistatin-related proteins - genetics - physiology |
4 |
|
follow‐up |
4 |
|
forkhead transcription factor |
4 |
|
founder effect |
4 |
|
foxo3a |
4 |
|
gene dosage |
4 |
|
gene expression - drug effects |
4 |
|
gene expression profiling - methods |
4 |
|
gene expression regulation, neoplastic - drug effects |
4 |
|
gene-expression-regulation,-neoplastic |
4 |
|
general gynaecology |
4 |
|
genetic markers |
4 |
|
genetics, population |
4 |
|
genome, human |
4 |
|
genomic instability - genetics |
4 |
|
germ-line mutation - genetics |
4 |
|
gestational trophoblastic disease - genetics |
4 |
|
gestational trophoblastic diseases |
4 |
|
gestational trophoblastic neoplasms - genetics - pathology - therapy |
4 |
|
gnrh |
4 |
|
gpi-linked proteins |
4 |
|
gro-α |
4 |
|
gtp-binding proteins - metabolism |
4 |
|
gynecologic cancer |
4 |
|
gynecologic oncology |
4 |
|
gynecological cancers |
4 |
|
health knowledge, attitudes, practice |
4 |
|
health surveys |
4 |
|
hedgehog proteins - metabolism |
4 |
|
hela cells |
4 |
|
hepatitis c - complications |
4 |
|
hepatitis c virus |
4 |
|
hepatocellular carcinoma |
4 |
|
high throughput screen |
4 |
|
high-grade squamous intraepithelial lesions |
4 |
|
high-risk gestational trophoblastic disease |
4 |
|
hippo/yap1/pathway |
4 |
|
hk2 |
4 |
|
homeodomain proteins - genetics - metabolism |
4 |
|
hpv vaccine |
4 |
|
hpv vaccine perception |
4 |
|
hpv vaccine questionnaire |
4 |
|
hpv vaccine survey |
4 |
|
human papilloma virus (hpv) |
4 |
|
human papillomavirus infection (hpv‐1) |
4 |
|
hydatidiform mole - genetics - metabolism - pathology |
4 |
|
hydatidiform mole - metabolism |
4 |
|
hydatidiform-mole-chemistry |
4 |
|
hydroxamic acids - pharmacology |
4 |
|
igf-1r |
4 |
|
igfbp3 |
4 |
|
il-8 |
4 |
|
interphase |
4 |
|
isothermal amplification |
4 |
|
jnk |
4 |
|
laparoscopic |
4 |
|
laparoscopy |
4 |
|
laparotomy |
4 |
|
liver neoplasms - pathology - surgery |
4 |
|
low-grade squamous intraepithelial lesions |
4 |
|
ly294002 |
4 |
|
mapk signaling |
4 |
|
mass screening - methods |
4 |
|
membrane glycoproteins - genetics - metabolism |
4 |
|
metformin |
4 |
|
methylation profile |
4 |
|
methylome profiling |
4 |
|
microsatellite instability analysis |
4 |
|
microwave coagulation |
4 |
|
microwaves - therapeutic use |
4 |
|
mir-193a-3p |
4 |
|
mismatch repair deficiency |
4 |
|
mitochondrial dna |
4 |
|
mitochondrial microsatellite instability |
4 |
|
molecular diagnostic techniques - methods |
4 |
|
motility |
4 |
|
mtor |
4 |
|
multienzyme complexes - genetics |
4 |
|
multigene panel |
4 |
|
nanog |
4 |
|
neoplasm proteins - analysis |
4 |
|
neoplasm proteins - genetics |
4 |
|
neoplasm proteins - metabolism |
4 |
|
neoplasm, residual |
4 |
|
neoplastic stem cells - physiology |
4 |
|
nerve growth factors - antagonists & inhibitors - genetics - pharmacology |
4 |
|
nfκb signaling |
4 |
|
notch |
4 |
|
nuclear proteins - genetics |
4 |
|
nurr1 |
4 |
|
oct4 |
4 |
|
octamer transcription factor-3 - genetics - metabolism |
4 |
|
oncogene proteins, viral - biosynthesis |
4 |
|
osteopontin |
4 |
|
ovarian neoplasms - enzymology - genetics - pathology |
4 |
|
ovarian neoplasms - genetics - metabolism |
4 |
|
ovarian neoplasms - pathology - physiopathology |
4 |
|
ovarian tumors |
4 |
|
ovary - cytology - metabolism |
4 |
|
ovary - metabolism |
4 |
|
ovary cancer |
4 |
|
p-cadherin |
4 |
|
p120ctn |
4 |
|
p21-activated kinases - antagonists and inhibitors - genetics - physiology |
4 |
|
pak1 |
4 |
|
pak2 |
4 |
|
papillomaviridae - classification - genetics - isolation and purification |
4 |
|
papillomaviridae - immunology |
4 |
|
papillomavirus e7 proteins |
4 |
|
papillomavirus infections - complications - enzymology - genetics |
4 |
|
papillomavirus infections - prevention & control - virology |
4 |
|
papillomavirus vaccines |
4 |
|
peritoneal metastases |
4 |
|
peritoneal neoplasms |
4 |
|
pilot projects |
4 |
|
placenta |
4 |
|
placenta - cytology |
4 |
|
placenta - physiology |
4 |
|
placenta-chemistry |
4 |
|
placental site |
4 |
|
placental site trophoblastic tumor |
4 |
|
placental-site tro phoblastic tumor |
4 |
|
polymerase chain reaction - methods |
4 |
|
prediction model |
4 |
|
predictive value of tests |
4 |
|
pregnancy complications, infectious - diagnosis - enzymology - virology |
4 |
|
pregnancy complications, infectious - epidemiology - pathology |
4 |
|
pregnancy complications, neoplastic - pathology |
4 |
|
pregnancy trimester, first |
4 |
|
pregnancy trimester, third - genetics |
4 |
|
pregnancy trimesters |
4 |
|
primary care |
4 |
|
prkaa1 |
4 |
|
promoter regions (genetics) |
4 |
|
prospective studies |
4 |
|
prostate stem cell antigen |
4 |
|
prostatic neoplasms - genetics - metabolism - pathology |
4 |
|
protein-serine-threonine kinases - genetics |
4 |
|
proto-oncogene proteins c-bcl-2 - metabolism |
4 |
|
proto-oncogene-proteins-c-myc-analysis |
4 |
|
psychological well-being |
4 |
|
questionnaires |
4 |
|
radiation tolerance - genetics |
4 |
|
radio waves |
4 |
|
radiofrequency ablation |
4 |
|
radioresistance |
4 |
|
receptor, erbb-2 - metabolism |
4 |
|
receptor, igf type 1 - antagonists and inhibitors - genetics - physiology |
4 |
|
receptor,-macrophage-colony-stimulating-factor-analysis |
4 |
|
receptors, cell surface - metabolism |
4 |
|
receptors, fsh - genetics |
4 |
|
recurrence of hcc |
4 |
|
rho gtp-binding proteins - metabolism |
4 |
|
rna - metabolism |
4 |
|
rna, messenger - analysis |
4 |
|
rna, messenger - biosynthesis - genetics |
4 |
|
rna, small interfering - pharmacology |
4 |
|
rna-binding proteins - genetics - metabolism |
4 |
|
robot-assisted |
4 |
|
ros |
4 |
|
sarcoma, endometrial stromal - genetics - pathology - ultrastructure |
4 |
|
self-renewal |
4 |
|
semi-quantitative fluorescent differential pcr |
4 |
|
sentis hpv |
4 |
|
serpins - genetics - pharmacology |
4 |
|
sialoglycoproteins - metabolism |
4 |
|
signal transduction - genetics |
4 |
|
signal transduction - physiology |
4 |
|
sox7 |
4 |
|
spain - epidemiology |
4 |
|
squamous cell carcinoma |
4 |
|
stat3 |
4 |
|
stat3 transcription factor - biosynthesis - genetics - metabolism |
4 |
|
sulfites - chemistry |
4 |
|
suppression subtractive hybridization |
4 |
|
surgery |
4 |
|
tamoxifen |
4 |
|
telomerase - analysis |
4 |
|
telomerase - metabolism |
4 |
|
telomerase repeat amplification protocol |
4 |
|
telomere - enzymology - genetics |
4 |
|
temperature |
4 |
|
tgfβ |
4 |
|
therapeutic molecular target |
4 |
|
therapeutic target |
4 |
|
time factors |
4 |
|
transcription factors - genetics |
4 |
|
transcription factors - metabolism |
4 |
|
transforming growth factor beta - physiology |
4 |
|
transforming growth factor beta1 |
4 |
|
treatment outcome |
4 |
|
trf |
4 |
|
trophoblasts - physiology |
4 |
|
trophoblasts-chemistry |
4 |
|
tumor grading |
4 |
|
tumor suppressor genes |
4 |
|
tumor suppressor protein p53 - genetics - metabolism |
4 |
|
tumor virus infections - epidemiology - pathology |
4 |
|
tumor-stroma interactions |
4 |
|
uterine cervical diseases - microbiology |
4 |
|
uterine cervical dysplasia - diagnosis - enzymology - pathology - virology |
4 |
|
uterine cervical neoplasms - diagnosis - enzymology - pathology - virology |
4 |
|
uterine cervical neoplasms - enzymology |
4 |
|
uterine cervical neoplasms - enzymology - genetics - virology |
4 |
|
uterine cervical neoplasms - metabolism - radiotherapy |
4 |
|
uterine cervical neoplasms - prevention & control - virology |
4 |
|
uterine cervicitis - enzymology - pathology - virology |
4 |
|
uterine cervix |
4 |
|
uterine leiomyosarcoma |
4 |
|
uterine neoplasms - genetics - metabolism |
4 |
|
uterine-neoplasms-enzymology |
4 |
|
venous thromboembolism |
4 |
|
x chromosome |
4 |
|
18f-fdg pet/ct |
3 |
|
abdominal hysterectomy |
3 |
|
abortion, spontaneous |
3 |
|
abortion, spontaneous - immunology |
3 |
|
abortion, spontaneous - metabolism |
3 |
|
actin |
3 |
|
actins - metabolism - ultrastructure |
3 |
|
adaptor proteins, signal transducing - genetics - metabolism |
3 |
|
adenocarcinoma |
3 |
|
adenocarcinoma - pathology |
3 |
|
adenocarcinoma, clear cell - drug therapy - pathology - radiotherapy |
3 |
|
adenocarcinoma, clear cell - genetics - pathology |
3 |
|
adenocarcinoma, clear cell - pathology - therapy |
3 |
|
adenocarcinoma, mucinous - diagnosis - pathology - therapy - ultrastructure |
3 |
|
adenomyosis |
3 |
|
adjuvants |
3 |
|
age factors |
3 |
|
aicar |
3 |
|
ais |
3 |
|
alphapapillomavirus - isolation and purification |
3 |
|
alternative splicing |
3 |
|
amp-activated protein kinase |
3 |
|
ampk alpha 2 |
3 |
|
ampk subunits |
3 |
|
antigens, neoplasm - metabolism |
3 |
|
antineoplastic agents - therapeutic use |
3 |
|
antineoplastic agents, phytogenic - pharmacology |
3 |
|
antineoplastic combined chemotherapy protocols - administration & dosage |
3 |
|
anxiety - etiology |
3 |
|
apoferritins |
3 |
|
apoptosis - physiology |
3 |
|
apoptosis - physiology - radiation effects |
3 |
|
apoptosis regulatory proteins - genetics - metabolism - physiology |
3 |
|
apoptotic (ai) and mitotic indices (mi) |
3 |
|
apoptotic activity |
3 |
|
asian continental ancestry group - ethnology |
3 |
|
asian women |
3 |
|
aspp1 |
3 |
|
attitude to health |
3 |
|
atypical cytology |
3 |
|
bcl2a1 |
3 |
|
beliefs |
3 |
|
beta-catenin |
3 |
|
bitter melono |
3 |
|
brachytherapy - methods |
3 |
|
brain-derived neurotrophic factor - biosynthesis |
3 |
|
brenner tumor - diagnosis - metabolism - pathology |
3 |
|
brenner tumour |
3 |
|
c-erbb-2 |
3 |
|
c-fms |
3 |
|
c-kit |
3 |
|
c-myc |
3 |
|
ca-125 antigen - blood |
3 |
|
ca125 |
3 |
|
camkk |
3 |
|
cancer |
3 |
|
cancer cell growth |
3 |
|
cancer radiotherapy |
3 |
|
cancer screening |
3 |
|
carboplatin |
3 |
|
carcinoid tumor - diagnosis - pathology - therapy - ultrastructure |
3 |
|
carcinoma |
3 |
|
carcinoma - enzymology - mortality - pathology |
3 |
|
carcinoma in situ - pathology |
3 |
|
carcinoma of cervix |
3 |
|
carcinoma, endometrioid - chemistry - pathology |
3 |
|
carcinoma, non-small-cell lung - genetics - metabolism - pathology |
3 |
|
carcinoma, squamous cell - diagnosis - genetics |
3 |
|
carcinoma, squamous cell - genetics - mortality - surgery - virology |
3 |
|
carcinoma, squamous cell - metabolism - mortality - virology |
3 |
|
carcinoma, squamous cell - pathology |
3 |
|
carcinoma, squamous cell - pathology - radiotherapy - surgery |
3 |
|
carcinoma, transitional cell - diagnosis - metabolism - pathology |
3 |
|
carcinoma,-squamous-cell-metabolism |
3 |
|
caspase |
3 |
|
cathepsin d |
3 |
|
cathepsin d - chemistry |
3 |
|
cdc42 |
3 |
|
cell cycle - physiology |
3 |
|
cell division |
3 |
|
cell movement - genetics |
3 |
|
cell movement - physiology |
3 |
|
cell signaling |
3 |
|
cell transformation, neoplastic - genetics |
3 |
|
cell transformation, viral - genetics |
3 |
|
cervical carcinoma and prognosis |
3 |
|
cervical intraepithelial neoplasia - genetics - metabolism |
3 |
|
cervix uteri - microbiology |
3 |
|
cervix uteri - pathology - radiation effects |
3 |
|
cervix uteri - pathology - virology |
3 |
|
chemoirradiation |
3 |
|
chi-square distribution |
3 |
|
chinese women |
3 |
|
choriocarcinoma - complications - surgery |
3 |
|
choriocarcinoma - diagnosis - immunology |
3 |
|
choriocarcinoma - genetics - metabolism - pathology |
3 |
|
choriocarcinoma - metabolism |
3 |
|
choriocarcinoma, non-gestational - pathology - therapy |
3 |
|
choriocarcinomas |
3 |
|
chorionic gonadotropin - metabolism |
3 |
|
chromosomes, human, pair 11 - genetics |
3 |
|
chromosomes, human, pair 16 - genetics |
3 |
|
chromosomes, human, pair 17 - genetics |
3 |
|
clear cell adenocarcinoma |
3 |
|
clear cell carcinoma |
3 |
|
comparative genomic hybridisation |
3 |
|
copy number |
3 |
|
cyclin-dependent kinase inhibitor p21 - metabolism |
3 |
|
cyclind1 |
3 |
|
cyclins - metabolism |
3 |
|
cyclophosphamide - administration & dosage - adverse effects |
3 |
|
cystadenocarcinoma, mucinous - genetics - pathology |
3 |
|
cystadenocarcinoma, serous - chemistry - pathology |
3 |
|
cystadenocarcinoma, serous - genetics - pathology |
3 |
|
cystadenoma - enzymology - mortality - pathology |
3 |
|
cystadenoma, mucinous - chemistry - pathology |
3 |
|
cystadenoma, serous - chemistry - pathology |
3 |
|
cytoskeleton - metabolism - ultrastructure |
3 |
|
d-loop |
3 |
|
daidzein |
3 |
|
diffusion |
3 |
|
diffusion-weighted mri |
3 |
|
dinucleotide repeats |
3 |
|
dj-1 |
3 |
|
dna amplification |
3 |
|
dna replication - genetics |
3 |
|
dna topoisomerases, type ii - analysis |
3 |
|
dna, complementary - genetics |
3 |
|
dna, mitochondrial - blood - genetics |
3 |
|
dna, mitochondrial - genetics - isolation & purification - metabolism |
3 |
|
dna, mitochondrial - genetics - metabolism |
3 |
|
dna, neoplasm - blood - genetics |
3 |
|
dna-binding proteins - biosynthesis - genetics |
3 |
|
dock180 expression |
3 |
|
drugs, chinese herbal - adverse effects - therapeutic use |
3 |
|
e2 binding sites methylation |
3 |
|
egfr |
3 |
|
endometrial neoplasms - pathology |
3 |
|
endometrial neoplasms - virology |
3 |
|
endometriosis |
3 |
|
endometriosis - diagnosis - pathology |
3 |
|
enzymes - genetics |
3 |
|
epidermal growth factor receptor |
3 |
|
epithelial cells |
3 |
|
epithelial cells - metabolism - pathology |
3 |
|
epithelioid cells - drug effects - pathology |
3 |
|
epithelioid trophoblastc tumour |
3 |
|
erb-041 |
3 |
|
esophageal neoplasms - genetics - mortality - surgery - virology |
3 |
|
esophagectomy |
3 |
|
esophagus - virology |
3 |
|
fallopian tubes - pathology |
3 |
|
ferritins |
3 |
|
fgf9 |
3 |
|
filter in-situ-hybridization |
3 |
|
follow-up |
3 |
|
ftl |
3 |
|
gemcitabine |
3 |
|
gene deletion |
3 |
|
gene knockdown techniques |
3 |
|
genes,-p53-genetics |
3 |
|
genistein |
3 |
|
genital neoplasms, female - epidemiology - pathology |
3 |
|
globins - genetics |
3 |
|
grb7 adaptor protein - genetics - metabolism - physiology |
3 |
|
green fluorescent proteins - genetics - metabolism |
3 |
|
gynecologic surgical procedures |
3 |
|
hormone receptors |
3 |
|
hpv infection |
3 |
|
hpv vaccination |
3 |
|
human papillomavirus (hpv) 16 |
3 |
|
human papillomavirus (hpv) 18 |
3 |
|
human papillomavirus 16 |
3 |
|
human papillomavirus 18 |
3 |
|
hydatidiform mole - blood - complications - drug therapy - surgery |
3 |
|
hydatidiform mole - diagnosis - immunology |
3 |
|
hydatidiform mole - enzymology |
3 |
|
hydatidiform mole - genetics - metabolism |
3 |
|
hydatidiform mole - immunology - pathology |
3 |
|
hypermethylation |
3 |
|
hypoxia |
3 |
|
igfbp1 |
3 |
|
immune function |
3 |
|
immunologic |
3 |
|
immunology |
3 |
|
incidence |
3 |
|
individuality |
3 |
|
infant, newborn |
3 |
|
inhibitor of apoptotic protein (iap) |
3 |
|
insulin-like growth factor binding protein 1 - genetics |
3 |
|
intracellular signaling peptides and proteins - genetics |
3 |
|
intravoxel incoherent motion |
3 |
|
intrinsic cell apoptosis |
3 |
|
invasion |
3 |
|
irradiation |
3 |
|
isoenzymes - genetics - metabolism |
3 |
|
ki-67 antigen |
3 |
|
ki-67 index |
3 |
|
knowledge |
3 |
|
laser capture microdissection |
3 |
|
leep |
3 |
|
liquid-based cervical cytology |
3 |
|
lkb1 |
3 |
|
lletz |
3 |
|
longitudinal |
3 |
|
lung neoplasms - genetics - metabolism - pathology |
3 |
|
lymphocytes - metabolism |
3 |
|
m30 |
3 |
|
macrophage polarization |
3 |
|
malignant melanoma |
3 |
|
map30 |
3 |
|
matrix metalloproteinase 14 - genetics - metabolism |
3 |
|
melanoma - epidemiology - pathology |
3 |
|
membrane proteins - biosynthesis |
3 |
|
membrane proteins - biosynthesis - genetics |
3 |
|
membrane proteins - genetics - metabolism |
3 |
|
mesoderm - metabolism - pathology |
3 |
|
metabolism |
3 |
|
methotrexate |
3 |
|
mi/ai ratio |
3 |
|
microsatellite instability |
3 |
|
microscopy, confocal |
3 |
|
mirna |
3 |
|
mitochondria - genetics |
3 |
|
mitogen-activated protein kinases - antagonists and inhibitors - metabolism |
3 |
|
mitosis - drug effects |
3 |
|
mitotic index |
3 |
|
mole |
3 |
|
monotherapy |
3 |
|
mucin |
3 |
|
mucins - secretion |
3 |
|
mullerian duct |
3 |
|
mutation- |
3 |
|
neoplasm grading |
3 |
|
neoplasm invasiveness - genetics - pathology |
3 |
|
neoplasm invasiveness - pathology |
3 |
|
neoplasm proteins - analysis - immunology |
3 |
|
neoplasm proteins/genetics |
3 |
|
neoplasm recurrence, local - pathology |
3 |
|
neoplasms, multiple primary - diagnosis - pathology - therapy - ultrastructure |
3 |
|
neovascularization, pathologic - genetics - metabolism |
3 |
|
neuroendocrine and mucinous carcinoma |
3 |
|
non-small cell lung cancer |
3 |
|
nongestatational choriocarcinoma |
3 |
|
normal cervix |
3 |
|
nr4a2 |
3 |
|
nuclear proteins - biosynthesis - genetics |
3 |
|
nuclear proteins - immunology - metabolism |
3 |
|
oligonucleotide array sequence analysis - methods |
3 |
|
oncogene proteins - biosynthesis - genetics |
3 |
|
oncogenes |
3 |
|
ovarian and peritoneal cancers |
3 |
|
ovarian cancer recurrence |
3 |
|
ovarian neoplasms - chemistry - pathology |
3 |
|
ovarian neoplasms - diagnosis - metabolism - pathology |
3 |
|
ovarian neoplasms - diagnosis - pathology - therapy - ultrastructure |
3 |
|
ovarian neoplasms - drug therapy - immunology |
3 |
|
ovarian neoplasms - drug therapy - metabolism - pathology |
3 |
|
ovarian neoplasms - enzymology - mortality - pathology |
3 |
|
ovarian neoplasms - enzymology - pathology |
3 |
|
ovarian neoplasms - metabolism - mortality - pathology |
3 |
|
ovarian neoplasms - pathology - therapy |
3 |
|
ovarian neoplasms - virology |
3 |
|
ovarian tumor |
3 |
|
ovarian tumours |
3 |
|
ovary - cytology |
3 |
|
p21(waf1/cip1) |
3 |
|
p21-activated kinases - antagonists and inhibitors - genetics - metabolism |
3 |
|
p21-activated kinases - genetics - metabolism |
3 |
|
p53 arg-72 |
3 |
|
p53 codon 72 polymorphism |
3 |
|
p70 s6 kinase |
3 |
|
p73 |
3 |
|
paclitaxel |
3 |
|
paclitaxel - pharmacology |
3 |
|
pan-ras |
3 |
|
papillomaviridae - genetics - isolation & purification |
3 |
|
papillomavirus infections - complications - epidemiology - virology |
3 |
|
papillomavirus infections - diagnosis - psychology |
3 |
|
papillomavirus infections - epidemiology - mortality |
3 |
|
papillomavirus infections - ethnology - prevention & control |
3 |
|
papillomavirus infections - ethnology - prevention & control - psychology |
3 |
|
papillomavirus vaccines - therapeutic use |
3 |
|
patient acceptance of health care |
3 |
|
patient acceptance of health care - ethnology |
3 |
|
patient satisfaction - ethnology |
3 |
|
pelvic neoplasms - diagnosis - pathology |
3 |
|
peptides - genetics |
3 |
|
perfusion |
3 |
|
peritoneal carcinomatosis |
3 |
|
peritoneal metastasis |
3 |
|
physical examination |
3 |
|
placenta - cytology - metabolism - pathology |
3 |
|
placenta - enzymology |
3 |
|
placenta - immunology - pathology |
3 |
|
placental site trophoblastic tumour |
3 |
|
polymorphism, single-stranded conformational |
3 |
|
post lletz complications |
3 |
|
precancerous conditions - diagnosis - genetics |
3 |
|
pregnancy complications - metabolism - pathology |
3 |
|
pregnancy complications, neoplastic - genetics |
3 |
|
premetastatic niche |
3 |
|
prevention |
3 |
|
prognostic factor |
3 |
|
prognostic factors |
3 |
|
proliferating cell nuclear antigen |
3 |
|
proto-oncogenes - physiology |
3 |
|
psychology |
3 |
|
psychosocial adjustment |
3 |
|
pten |
3 |
|
pten phosphohydrolase - biosynthesis - genetics |
3 |
|
rac gtp-binding proteins - analysis - biosynthesis |
3 |
|
rac1 |
3 |
|
radiation tolerance - genetics - physiology |
3 |
|
rare diseases |
3 |
|
real-time polymerase chain reaction |
3 |
|
real-time quantitative pcr |
3 |
|
receptor, epidermal growth factor - metabolism |
3 |
|
receptor, trkb - biosynthesis |
3 |
|
receptors, estrogen - chemistry |
3 |
|
receptors, progesterone - chemistry |
3 |
|
repressor proteins |
3 |
|
repressor proteins - biosynthesis - genetics |
3 |
|
ribonuclease protection assay |
3 |
|
ribosomal protein s6 kinases, 70-kda - genetics - metabolism |
3 |
|
ribosomal protein s6 kinases, 70-kda - physiology |
3 |
|
risk assessment |
3 |
|
rna |
3 |
|
rna, ribosomal - genetics |
3 |
|
rna, ribosomal, 16s - genetics |
3 |
|
rna, small interfering |
3 |
|
rna-binding proteins - genetics - metabolism - physiology |
3 |
|
serpins |
3 |
|
sexual behavior |
3 |
|
social hygiene clinic |
3 |
|
sox2 |
3 |
|
soxb1 transcription factors - genetics - metabolism |
3 |
|
staging |
3 |
|
stress, psychological - etiology |
3 |
|
tcf/lef-1 |
3 |
|
telomerase activity |
3 |
|
telomere |
3 |
|
terminal deoxynucleotidyl transferase (tdt)-mediated deoxyuracil triphosphate (dutp) nick-end labelling (tunel) |
3 |
|
timp3 |
3 |
|
tissue array |
3 |
|
tissue polypeptide antigen |
3 |
|
tp53 |
3 |
|
traditional chinese medicine |
3 |
|
transition |
3 |
|
transitional cell carcinoma |
3 |
|
trkb |
3 |
|
trophoblastic disease |
3 |
|
trophoblastic neoplasms - complications - drug therapy - surgery |
3 |
|
trophoblastic neoplasms - diagnosis - immunology |
3 |
|
trophoblastic neoplasms - genetics |
3 |
|
trophoblastic tumor, placental site - metabolism - pathology |
3 |
|
trophoblasts - metabolism - physiology |
3 |
|
tumor debulking |
3 |
|
tumor microenvironment |
3 |
|
tumor suppressor protein p53 - metabolism |
3 |
|
tumor suppressor proteins - genetics - metabolism - physiology |
3 |
|
tumor virus infections - epidemiology |
3 |
|
tumor virus infections - epidemiology - mortality |
3 |
|
tumor-associated macrophages |
3 |
|
tumor-suppressor-protein-p53-genetics |
3 |
|
tumor-suppressor-protein-p53-metabolism |
3 |
|
tumorigenicity |
3 |
|
ultrasonography |
3 |
|
uterine anomaly |
3 |
|
uterine cervical diseases - epidemiology |
3 |
|
uterine cervical neoplasms - diagnosis - genetics |
3 |
|
uterine cervical neoplasms - diagnosis - pathology |
3 |
|
uterine cervical neoplasms - drug therapy - pathology - radiotherapy |
3 |
|
uterine cervical neoplasms - epidemiology - pathology - surgery |
3 |
|
uterine cervical neoplasms - ethnology - virology |
3 |
|
uterine cervical neoplasms - genetics - metabolism |
3 |
|
uterine cervical neoplasms - genetics - mortality - pathology - radiotherapy |
3 |
|
uterine cervical neoplasms - genetics - virology |
3 |
|
uterine cervical neoplasms - metabolism |
3 |
|
uterine cervical neoplasms - metabolism - mortality - virology |
3 |
|
uterine cervical neoplasms - microbiology |
3 |
|
uterine cervical neoplasms - pathology - radiotherapy - surgery |
3 |
|
uterine cervical neoplasms - prevention and control - virology |
3 |
|
uterine cervical neoplasms - psychology |
3 |
|
uterine cervical neoplasms - virology |
3 |
|
uterine cervix cancer |
3 |
|
uterine neoplasms - blood - complications - drug therapy - surgery |
3 |
|
uterine neoplasms - diagnosis - immunology |
3 |
|
uterine neoplasms - diagnosis - pathology |
3 |
|
uterine neoplasms - genetics |
3 |
|
uterine neoplasms - pathology - therapy |
3 |
|
uterus - abnormalities - pathology |
3 |
|
vagina |
3 |
|
vaginal intraepithelial neoplasia |
3 |
|
vaginal neoplasms - epidemiology - pathology - radiotherapy - surgery |
3 |
|
vaginal neoplasms - pathology |
3 |
|
varian cancer |
3 |
|
viral load |
3 |
|
vulva |
3 |
|
vulvar neoplasms - epidemiology - pathology - radiotherapy - surgery |
3 |
|
wnt |
3 |
|
wnt/β-catenin |
3 |
|
women's health issues |
3 |
|
"favor neoplasia" |
2 |
|
"nos" |
2 |
|
'favor neoplasia' |
2 |
|
'nos' |
2 |
|
3d ultrasound |
2 |
|
adenocarcinoma - blood - pathology |
2 |
|
adenocarcinoma - diagnosis - pathology |
2 |
|
adenocarcinoma - diagnosis - pathology - physiopathology |
2 |
|
adenocarcinoma - etiology - metabolism |
2 |
|
adenocarcinoma - virology |
2 |
|
adenocarcinoma of cervix |
2 |
|
adenocarcinoma, mucinous - drug therapy - pathology |
2 |
|
adenosarcoma |
2 |
|
adenoviral vector |
2 |
|
agc |
2 |
|
agus |
2 |
|
ampk activator |
2 |
|
analysis of variance |
2 |
|
angiography |
2 |
|
antibiotics, antineoplastic - therapeutic use |
2 |
|
anticancer |
2 |
|
antigens, neoplasm - analysis |
2 |
|
antigens, neoplasm - blood |
2 |
|
antineoplastic agents - adverse effects - therapeutic use |
2 |
|
antioxidant activity |
2 |
|
antisense oligonucleotide |
2 |
|
apgar score |
2 |
|
arteries - surgery |
2 |
|
asia |
2 |
|
asia - epidemiology |
2 |
|
asia pacific |
2 |
|
asphyxia neonatorum - etiology |
2 |
|
atp cell viability assay |
2 |
|
attitudes |
2 |
|
bar |
2 |
|
bax/bcl-2 |
2 |
|
bcl-2 |
2 |
|
biopsy - statistics & numerical data |
2 |
|
birth injuries - etiology |
2 |
|
birth weight |
2 |
|
bitter melon |
2 |
|
bleomycin - administration & dosage - adverse effects |
2 |
|
breast carcinoma |
2 |
|
ca-19-9 antigen - blood |
2 |
|
ca15.3 |
2 |
|
ca19.9 |
2 |
|
cancers |
2 |
|
capsid proteins |
2 |
|
carboplatin - pharmacology |
2 |
|
carcinoembryonic antigen |
2 |
|
carcinoembryonic antigen - blood |
2 |
|
carcinoma in situ - diagnosis - epidemiology - etiology - pathology |
2 |
|
carcinoma in situ - diagnosis - pathology |
2 |
|
carcinoma of the cervix |
2 |
|
carcinoma of the ovary |
2 |
|
carcinoma, adenosquamous - diagnosis - pathology - physiopathology |
2 |
|
carcinoma, squamous cell - diagnosis - pathology - physiopathology |
2 |
|
carcinoma, squamous cell - epidemiology - genetics - virology |
2 |
|
carcinoma, squamous cell - epidemiology - prevention & control - virology |
2 |
|
carcinoma, squamous cell - mortality - pathology |
2 |
|
carcinoma,-squamous-cell-microbiology |
2 |
|
cell metabolism |
2 |
|
cell survival - drug effects |
2 |
|
cervical |
2 |
|
cervical cancer cell lines |
2 |
|
cervical carcinoma |
2 |
|
cervical intraepithelial neoplasia - diagnosis - epidemiology - etiology - pathology |
2 |
|
cervical intraepithelial neoplasia - diagnosis - pathology |
2 |
|
cervical intraepithelial neoplasia - pathology - therapy |
2 |
|
cervical intraepithelial neoplasia - prevention & control - psychology |
2 |
|
cervical intraepithelial neoplasia - prevention & control - virology |
2 |
|
cervix carcinoma |
2 |
|
cervix uteri - pathology |
2 |
|
cervix-uteri-microbiology |
2 |
|
chemotherapy, adjuvant - methods |
2 |
|
chinese adolescent girls |
2 |
|
choriocarcinoma - drug therapy - secondary |
2 |
|
choriocarcinoma - pathology - therapy |
2 |
|
chorionic villi |
2 |
|
cisplatin - administration & dosage |
2 |
|
cisplatin - administration & dosage - adverse effects |
2 |
|
clinical trials as topic |
2 |
|
combined modality therapy - methods |
2 |
|
complications |
2 |
|
consensus sequence |
2 |
|
conservative treatment |
2 |
|
consumer health information - methods |
2 |
|
cost |
2 |
|
cyclophosphamide |
2 |
|
cyclophosphamide - administration & dosage |
2 |
|
dexamethasone - administration & dosage - adverse effects |
2 |
|
dilatation and curettage |
2 |
|
dna, viral - analysis - genetics |
2 |
|
doxorubicin - administration & dosage - adverse effects |
2 |
|
drug screening assays, antitumor |
2 |
|
embolization, therapeutic |
2 |
|
endocrine system diseases - drug therapy - pathology |
2 |
|
endometrial and ovarian carcinomas |
2 |
|
endometrial hyperplasia - diagnosis - pathology |
2 |
|
endometrial neoplasms - diagnosis - surgery - therapy |
2 |
|
epidemiology |
2 |
|
epirubicin - therapeutic use |
2 |
|
erbb2 mutation |
2 |
|
esophageal neoplasms - epidemiology - genetics - virology |
2 |
|
esophagus |
2 |
|
extraction, obstetrical - instrumentation |
2 |
|
fear |
2 |
|
fertility preservation |
2 |
|
gene expression regulation, neoplastic - physiology |
2 |
|
gene transfer |
2 |
|
genes, bcl-2 |
2 |
|
genital neoplasms, female - complications |
2 |
|
genital neoplasms, female - pathology |
2 |
|
gestational trophoblastic disease - complications - epidemiology |
2 |
|
gestational trophoblastic disease - complications - psychology - therapy |
2 |
|
gestational trophoblastic meoplasia |
2 |
|
gestational trophoblastic neoplasms |
2 |
|
growth arrest and dna damage inducible protein 45 |
2 |
|
growth arrest and dna damage inducible protein 45 alpha |
2 |
|
growth arrest/apoptosis |
2 |
|
gynaecological cancers |
2 |
|
gynecological malignancy |
2 |
|
health personnel |
2 |
|
healthcare providers |
2 |
|
heart neoplasms - secondary |
2 |
|
hemorrhage - etiology |
2 |
|
hemostatic techniques - utilization |
2 |
|
high-dose cis-platinum |
2 |
|
histology |
2 |
|
hong kong chinese |
2 |
|
hpv dna |
2 |
|
hpv education |
2 |
|
human papillomavirus testing |
2 |
|
hydatidiform mole - blood |
2 |
|
hysterectomy - psychology |
2 |
|
intermediate filament proteins - metabolism |
2 |
|
intestinal metaplasia |
2 |
|
intracardiac tumor |
2 |
|
intravenous leiomyomatosis |
2 |
|
jaundice, neonatal - etiology |
2 |
|
keratin-20 |
2 |
|
keratin-7 |
2 |
|
kidney - drug effects |
2 |
|
kras mutation |
2 |
|
laser-captured micro-dissection |
2 |
|
leiomyoma - epidemiology - secondary |
2 |
|
leucovorin - administration & dosage - adverse effects |
2 |
|
ligation |
2 |
|
live fetus |
2 |
|
low grade squamous intraepithelial lesions (lsil) |
2 |
|
lung - drug effects - physiopathology |
2 |
|
lymph node excision |
2 |
|
lymphatic metastasis |
2 |
|
lymphocyst |
2 |
|
lymphoma, non-hodgkin - drug therapy - physiopathology |
2 |
|
malformation |
2 |
|
medical records |
2 |
|
medicinal fungi |
2 |
|
medicinal plants |
2 |
|
meta-analysis |
2 |
|
methotrexate - administration & dosage - adverse effects |
2 |
|
methyltransferase |
2 |
|
mitochondria |
2 |
|
mitochondrial dna alterations |
2 |
|
mitogen activated protein kinase kinase 4 |
2 |
|
mitomycin |
2 |
|
mitomycin c |
2 |
|
mitomycins - administration & dosage |
2 |
|
momordica charantia |
2 |
|
msp |
2 |
|
mucin-1 - blood |
2 |
|
neoplasm recurrence, local - therapy |
2 |
|
neoplasms, germ cell and embryonal - drug therapy - pathology |
2 |
|
neoplasms, multiple primary - pathology |
2 |
|
nervous system neoplasms - drug therapy - pathology |
2 |
|
nucleic acid hybridization |
2 |
|
nutraceuticals |
2 |
|
oncogene proteins, viral - genetics |
2 |
|
oncogene proteins, viral - isolation & purification |
2 |
|
organ sparing treatments |
2 |
|
ovarian |
2 |
|
ovarian neoplasms - drug therapy |
2 |
|
ovariectomy |
2 |
|
p21(waf1) |
2 |
|
palliation |
2 |
|
palliative care |
2 |
|
papillomaviridae-isolation-and-purification |
2 |
|
papillomavirus infections - complications - virology |
2 |
|
papillomavirus infections - epidemiology - prevention & control - virology |
2 |
|
papillomavirus infections - prevention & control - psychology |
2 |
|
papillomavirus infections - prevention and control |
2 |
|
papillomavirus vaccines - administration & dosage |
2 |
|
partial mole |
2 |
|
pathology review |
2 |
|
patient education as topic |
2 |
|
pcr |
2 |
|
pediatrics |
2 |
|
pelvic lymphadenectomy |
2 |
|
peptides - analysis |
2 |
|
persistent trophoblastic disease |
2 |
|
pik3ca mutation |
2 |
|
placental-site trophoblastic tumour |
2 |
|
plasma dna |
2 |
|
pleural effusion, malignant - etiology - therapy |
2 |
|
pleurodesis |
2 |
|
postpartum |
2 |
|
prb |
2 |
|
precancerous conditions - diagnosis - epidemiology - pathology - physiopathology |
2 |
|
prednisone - administration & dosage - adverse effects |
2 |
|
pregnancy complications, neoplastic - diagnosis - epidemiology - pathology - physiopathology |
2 |
|
protein p73 |
2 |
|
proto-oncogene proteins - genetics |
2 |
|
proto-oncogene proteins c-bcl-2 - genetics |
2 |
|
psychosocial study |
2 |
|
pulmonary diffusing capacity - drug effects |
2 |
|
pyrosequencing |
2 |
|
quantitative pcr |
2 |
|
radiography, interventional |
2 |
|
radioimmunoassay |
2 |
|
radiosensitivity |
2 |
|
radiotherapy - methods |
2 |
|
random allocation |
2 |
|
recurrence |
2 |
|
referral and consultation |
2 |
|
relapse |
2 |
|
remission, spontaneous |
2 |
|
respiratory function tests |
2 |
|
retroperitoneal neoplasms - pathology |
2 |
|
safety |
2 |
|
school-based health education |
2 |
|
selective |
2 |
|
self concept |
2 |
|
serum |
2 |
|
sexual functioning |
2 |
|
significant pathology |
2 |
|
singapore |
2 |
|
social stigma |
2 |
|
soft tissue neoplasms - epidemiology - secondary |
2 |
|
spot and early morning urine |
2 |
|
squamous cell carcinoma antigen |
2 |
|
sscp |
2 |
|
staining and labeling |
2 |
|
stigma |
2 |
|
taiwan |
2 |
|
targeted therapy |
2 |
|
therapeutic embolization |
2 |
|
tissue polypeptide antigen - blood |
2 |
|
toxicity |
2 |
|
tp53 mutation |
2 |
|
treatment |
2 |
|
trophoblastic neoplasms - blood |
2 |
|
trophoblastic neoplasms - drug therapy - secondary |
2 |
|
trophoblastic neoplasms - psychology |
2 |
|
trophoblastic tumor, placental site - genetics - pathology |
2 |
|
tumor markers, biological |
2 |
|
tumor markers, biological - analysis - blood |
2 |
|
tumor markers, biological - blood |
2 |
|
tumor virus infections - complications - virology |
2 |
|
tumor-suppressor-protein-p53-analysis |
2 |
|
tumour markers |
2 |
|
type distribution |
2 |
|
undifferentiated endometrial sarcoma |
2 |
|
urethral adenocarcinoma |
2 |
|
urethral neoplasms - etiology - metabolism |
2 |
|
urethral neoplasms - pathology |
2 |
|
urethritis - complications |
2 |
|
urethritis glandularis |
2 |
|
urinary hcg-beta-core |
2 |
|
uterine |
2 |
|
uterine bleeding |
2 |
|
uterine cervical dysplasia - pathology - therapy |
2 |
|
uterine cervical neoplasms - blood - pathology |
2 |
|
uterine cervical neoplasms - diagnosis - pathology - physiopathology |
2 |
|
uterine cervical neoplasms - drug therapy - mortality - radiotherapy |
2 |
|
uterine cervical neoplasms - epidemiology - prevention & control - virology |
2 |
|
uterine cervical neoplasms - ethnology - prevention and control - virology |
2 |
|
uterine cervical neoplasms - mortality - pathology |
2 |
|
uterine cervical neoplasms - pathology - therapy |
2 |
|
uterine hemorrhage - etiology - radiography - therapy |
2 |
|
uterine neoplasms - blood |
2 |
|
uterine neoplasms - complications - epidemiology |
2 |
|
uterine neoplasms - psychology |
2 |
|
uterine-cervical-neoplasms-microbiology |
2 |
|
vacuum extraction, obstetrical - adverse effects - instrumentation |
2 |
|
vagina - injuries |
2 |
|
vaginal metastases |
2 |
|
vaginal neoplasms - drug therapy - secondary |
2 |
|
vaginal smears - statistics & numerical data |
2 |
|
vena cava, inferior |
2 |
|
vincristine - administration & dosage - adverse effects |
2 |
|
young women |
2 |
|
9vhpv |
1 |
|
9vhpv vaccine |
1 |
|
actuarial analysis |
1 |
|
adenocarcinoma - chemistry |
1 |
|
adenocarcinoma - complications |
1 |
|
adenocarcinoma - drug therapy - pathology - surgery |
1 |
|
adenocarcinoma - radiotherapy |
1 |
|
age distribution |
1 |
|
aids |
1 |
|
amifostine |
1 |
|
anal cancer |
1 |
|
anthropometry |
1 |
|
anti-bacterial agents - therapeutic use |
1 |
|
antibiotic prophylaxis |
1 |
|
antigens, tumor-associated, carbohydrate - blood |
1 |
|
antimetabolites, antineoplastic - therapeutic use |
1 |
|
antineoplastic agents, phytogenic - therapeutic use |
1 |
|
anxiety |
1 |
|
anxiety - etiology - prevention & control |
1 |
|
apoptosis - radiation effects |
1 |
|
ascites - etiology |
1 |
|
asgo |
1 |
|
barriers to uptake |
1 |
|
biopsy, needle - methods |
1 |
|
birthweight |
1 |
|
bleomycin - therapeutic use |
1 |
|
body height |
1 |
|
body weight |
1 |
|
brachytherapy - adverse effects |
1 |
|
breast diseases - diagnosis |
1 |
|
breast neoplasms - pathology - therapy |
1 |
|
breech presentation |
1 |
|
ca cervix |
1 |
|
ca-125 |
1 |
|
cancer staging |
1 |
|
carcinoma - diagnosis - epidemiology - therapy |
1 |
|
carcinoma - diagnosis - genetics - prevention & control |
1 |
|
carcinoma - drug therapy - pathology - surgery |
1 |
|
carcinoma - radiotherapy |
1 |
|
carcinoma, ductal, breast - pathology |
1 |
|
carcinoma, squamous cell - blood - immunology - radiotherapy |
1 |
|
carcinoma, squamous cell - chemistry |
1 |
|
carcinoma, squamous cell - diagnosis - pathology |
1 |
|
carcinoma, squamous cell - drug therapy - pathology |
1 |
|
carcinoma, squamous cell - immunology |
1 |
|
carcinoma, squamous cell - radiotherapy |
1 |
|
catheterization - methods |
1 |
|
cervical biopsy |
1 |
|
cervical cancer control |
1 |
|
cervical cancer prevention |
1 |
|
cervical caner |
1 |
|
cervical intraepithelial neoplasia - pathology |
1 |
|
cervical intraepithelial neoplasia - prevention & control |
1 |
|
cervical punch biopsy |
1 |
|
cervix cancer |
1 |
|
cervix uteri - chemistry |
1 |
|
cesarean section |
1 |
|
chemosensitivity |
1 |
|
chemotherapy, adjuvant |
1 |
|
child |
1 |
|
choriocarcinoma - pathology |
1 |
|
chorionic gonadotropin, beta subunit, human - blood |
1 |
|
classification |
1 |
|
clinical trial |
1 |
|
clinical trials |
1 |
|
colposcopy - methods - psychology |
1 |
|
communication |
1 |
|
complementary and alternative medicine |
1 |
|
contraception |
1 |
|
cost-benefit analysis |
1 |
|
cost-effective |
1 |
|
counseling |
1 |
|
counselling |
1 |
|
ct |
1 |
|
ct thorax |
1 |
|
cystadenocarcinoma - drug therapy - pathology - surgery |
1 |
|
cytodiagnosis - instrumentation |
1 |
|
cytotoxicity |
1 |
|
dactinomycin - administration & dosage |
1 |
|
dactinomycin - therapeutic use |
1 |
|
diagnosis |
1 |
|
doppler sonography |
1 |
|
dose-response relationship, radiation |
1 |
|
drainage - methods |
1 |
|
drug response |
1 |
|
embryonic and fetal development |
1 |
|
endometrial hyperplasia - pathology |
1 |
|
endometrial neoplasms |
1 |
|
endometrial neoplasms - pathology - surgery |
1 |
|
endometriosis - complications |
1 |
|
endometriosis - drug therapy - pathology - surgery |
1 |
|
endometrium - pathology |
1 |
|
epirubicin - adverse effects - therapeutic use |
1 |
|
epithelioid trophoblastic tumor |
1 |
|
etoposide - therapeutic use |
1 |
|
excision |
1 |
|
exenteration |
1 |
|
extraction, obstetrical - adverse effects |
1 |
|
extrauterine involvement |
1 |
|
fertility |
1 |
|
fetal death |
1 |
|
fetal growth retardation - diagnosis |
1 |
|
fetal membranes, premature rupture - complications |
1 |
|
fetus - anatomy & histology |
1 |
|
fever - prevention & control |
1 |
|
figo |
1 |
|
figo cancer report |
1 |
|
fluorouracil - administration & dosage |
1 |
|
folinic acid rescue |
1 |
|
genital neoplasms, female - classification - pathology |
1 |
|
genital warts |
1 |
|
geometric mean titers (gmts) |
1 |
|
gestational trophoblastic disease - diagnosis - pathology - radiography - therapy |
1 |
|
gestational trophoblastic disease - drug therapy - metabolism |
1 |
|
gestational trophoblastic tumor (gtt) |
1 |
|
glycosylation |
1 |
|
gtn |
1 |
|
gynecologic cancer patients |
1 |
|
hcg |
1 |
|
health education - organization & administration - trends |
1 |
|
health personnel - education |
1 |
|
health policy - trends |
1 |
|
health services accessibility - trends |
1 |
|
health-care professionals |
1 |
|
heart diseases - chemically induced |
1 |
|
height |
1 |
|
hemoperitoneum - etiology |
1 |
|
hepatic arteriogram (hag) |
1 |
|
hiv screening |
1 |
|
hpv vaccines |
1 |
|
human papillomavirus vaccine |
1 |
|
human rights |
1 |
|
hydatidiform mole - diagnosis |
1 |
|
hydatidiform mole - drug therapy |
1 |
|
infant mortality |
1 |
|
infant, low birth weight |
1 |
|
infant, small for gestational age |
1 |
|
infusions, intravenous |
1 |
|
intellectual disability - etiology |
1 |
|
intelligence |
1 |
|
key words: |
1 |
|
klf2 |
1 |
|
liver metastasis |
1 |
|
liver neoplasms - blood supply - radiography - secondary - therapy |
1 |
|
low-risk gestational trophoblastic disease |
1 |
|
maintenance therapy |
1 |
|
malaysia |
1 |
|
malignant mixed mullerian tumors |
1 |
|
malignant trophoblastic disease |
1 |
|
maternal age |
1 |
|
maternal health services - organization & administration - trends |
1 |
|
medical records systems, computerized - statistics and numerical data |
1 |
|
menopause - metabolism |
1 |
|
metastases |
1 |
|
methotrexate - therapeutic use |
1 |
|
methotrexate infusion |
1 |
|
mgtd |
1 |
|
micrometastasis |
1 |
|
moles |
1 |
|
monitoring |
1 |
|
monitoring, immunologic - economics - methods |
1 |
|
monitoring, physiologic |
1 |
|
monsel's solution |
1 |
|
mothers - psychology |
1 |
|
mr imaging |
1 |
|
myelotoxicity |
1 |
|
neoplasm recurrence, local - drug therapy |
1 |
|
neoplasm recurrence, local - immunology |
1 |
|
neoplasm recurrence, local - prevention & control |
1 |
|
neoplasm staging - classification |
1 |
|
neoplasm staging - methods |
1 |
|
neoplasms, glandular and epithelial - diagnosis - genetics - prevention & control |
1 |
|
neurologic examination |
1 |
|
neutropenia |
1 |
|
obstetric labor complications - diagnosis - etiology |
1 |
|
occult cancer |
1 |
|
ovarian neoplasms - blood - drug therapy - surgery |
1 |
|
ovarian neoplasms - classification - diagnosis - mortality - therapy |
1 |
|
ovarian neoplasms - complications |
1 |
|
ovarian neoplasms - diagnosis - genetics - prevention & control |
1 |
|
ovarian neoplasms - diagnosis - pathology - therapy |
1 |
|
ovarian neoplasms - drug therapy - pathology - surgery |
1 |
|
ovarian tumors of low malignant potential |
1 |
|
papillomavirus infections - complications - genetics |
1 |
|
papillomavirus infections - prevention & control |
1 |
|
papillomavirus vaccines - immunology |
1 |
|
patient compliance |
1 |
|
pazopanib |
1 |
|
pelvic exenteration |
1 |
|
pelvic ultrasound |
1 |
|
pelvis |
1 |
|
penile cancer |
1 |
|
peritoneal cytology |
1 |
|
persistent trophoblastic tumour (pit) |
1 |
|
physician-patient relations |
1 |
|
physicians |
1 |
|
platinum-resistant epithelial ovarian cancer |
1 |
|
postoperative period |
1 |
|
pregnancy complications, neoplastic |
1 |
|
pregnancy outcome |
1 |
|
premenopause |
1 |
|
progression-free survival |
1 |
|
proportional hazards models |
1 |
|
psychomotor performance |
1 |
|
public health education |
1 |
|
puerperal disorders - etiology |
1 |
|
pulsatile flow |
1 |
|
radiation monitoring - methods |
1 |
|
radio-therapy |
1 |
|
radiotherapy |
1 |
|
radiotherapy dosage |
1 |
|
radiotherapy, adjuvant |
1 |
|
radium - adverse effects |
1 |
|
receptors, estrogen - analysis |
1 |
|
receptors, progesterone - analysis |
1 |
|
recurrent ovarian cancer |
1 |
|
recurrent respiratory papillomatosis |
1 |
|
registries |
1 |
|
regression analysis |
1 |
|
remission induction |
1 |
|
reoperation |
1 |
|
reproductive performance |
1 |
|
republic of korea |
1 |
|
review |
1 |
|
sarcoma - pathology - therapy |
1 |
|
scc |
1 |
|
second opinion |
1 |
|
serum human chorionic gonadotrophin (hcg) monitoring |
1 |
|
skinfold thickness |
1 |
|
stage ia pgtd |
1 |
|
struma ovarii |
1 |
|
suction |
1 |
|
suction - methods |
1 |
|
suppuration - therapy |
1 |
|
survey |
1 |
|
teratoma - drug therapy |
1 |
|
thailand |
1 |
|
tomography, x-ray computed |
1 |
|
topotecan |
1 |
|
transcriptional regulation |
1 |
|
treatment of vain |
1 |
|
trophoblastic neoplasms - blood - diagnosis - drug therapy |
1 |
|
trophoblastic neoplasms - blood supply - drug therapy - ultrasonography |
1 |
|
trophoblastic neoplasms - pathology |
1 |
|
trophoblastic neoplasms - physiopathology - psychology |
1 |
|
trophoblastic tumor, placental site - radiography - ultrasonography |
1 |
|
tumor suppressor proteins - genetics - metabolism |
1 |
|
ultrasonography, doppler, color |
1 |
|
umbilical cord |
1 |
|
univariate & multivariate analysis |
1 |
|
urban population |
1 |
|
uterine cervical neoplasms - blood - drug therapy - immunology |
1 |
|
uterine cervical neoplasms - blood - immunology - radiotherapy |
1 |
|
uterine cervical neoplasms - chemistry |
1 |
|
uterine cervical neoplasms - drug therapy - pathology |
1 |
|
uterine cervical neoplasms - immunology |
1 |
|
uterine cervical neoplasms - mortality - pathology - therapy |
1 |
|
uterine cervical neoplasms - mortality - therapy |
1 |
|
uterine cervical neoplasms - pathology - radiotherapy |
1 |
|
uterine cervical neoplasms - prevention & control |
1 |
|
uterine cervical neoplasms - radiotherapy |
1 |
|
uterine diseases - therapy |
1 |
|
uterine hemorrhage - etiology |
1 |
|
uterine neoplasms - blood - diagnosis - drug therapy |
1 |
|
uterine neoplasms - blood supply - drug therapy - ultrasonography |
1 |
|
uterine neoplasms - diagnosis - epidemiology - therapy |
1 |
|
uterine neoplasms - pathology |
1 |
|
uterine neoplasms - physiopathology - psychology |
1 |
|
uterus - blood supply |
1 |
|
vaccination |
1 |
|
vaccine |
1 |
|
vacuum extraction, obstetrical - adverse effects |
1 |
|
vagina - pathology |
1 |
|
vaginal bleeding |
1 |
|
vaginal cancer |
1 |
|
vaginal diseases - therapy |
1 |
|
vaginal neoplasms - classification - diagnosis - mortality - therapy |
1 |
|
vaginal sarcoma |
1 |
|
vaginal stenosis |
1 |
|
vaginal-template implant |
1 |
|
value of life |
1 |
|
vincristine - administration & dosage |
1 |
|
vulval cancer |
1 |
|
vulvar neoplasms - pathology - therapy |
1 |
|
wee1 |
1 |
|
weight |
1 |
|
women over 25 years |
1 |
|
women's rights |
1 |
|
women's rights - education - trends |
1 |
|
workshop |
1 |
